Industry News
SK bioscience Initiates Global Clinical Trials of mRNA Japanese Encephalitis Vaccine Candidate
* SK bioscience's first mRNA vaccine candidate enters Phase 1/2 clinical trials inAustralia and New Zealand, with interim results expected by 2026 * Joint R&D project between SK and CEPI includes up to USD 40 million in initial funding support from CEPI * SK bioscience will expand its vaccin...
2025-02-25 21:00
3921
CARsgen Therapeutics Introduced Zhuhai SB Xinchuang to Accelerate Allogeneic CAR-T Cell Products Development in Mainland China
SHANGHAI, Feb. 25, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK, "CARsgen Therapeutics"), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces reaching agreements with an investment fund m...
2025-02-25 21:00
2880
Ascenda and Galileo Financial Technologies Collaborate to Elevate Card Loyalty Programs
Partnership combines Galileo's technology platform and Ascenda's loyalty expertise to simplify and power card loyalty programs NEW YORK, Feb. 25, 2025 /PRNewswire/ -- Ascenda, the industry leader in loyalty-as-a-service, has partnered with Galileo Financial Technologies, SoFi Technologies, Inc.'...
2025-02-25 21:00
2527
Kangpu Biopharmaceuticals Received IND Approval from NMPA for KPG-818 to Treat Relapsed/Refractory Multiple Myeloma
HEFEI, China, Feb. 25, 2025 /PRNewswire/ -- Kangpu Biopharmaceuticals, Ltd. ("Kangpu") today announced that the Company has received IND approval from the CDE (Center for Drug Evaluation) of China National Medical Products Administration (NMPA) for KPG-818 for the treatment of relapsed/refractory...
2025-02-25 21:00
2429
RoboSense Achieves Milestone with Production and Delivery of Its 1 Millionth LiDAR
SHENZHEN, China, Feb. 25, 2025 /PRNewswire/ -- On February 21, RoboSense (2498.HK), an AI-driven robotics technology company that supplies industry-leading incremental components and solutions for the robotics market, held a ceremony inShenzhen to celebrate the production of its 1 millionth LiDAR...
2025-02-25 20:34
5126
Euro Tech Holdings Company Limited Reports Contracts Awarded to PACT
HONG KONG, Feb. 25, 2025 /PRNewswire/ -- Euro Tech Holdings Company Limited (Nasdaq: CLWT) today announced that its majority-owned subsidiary, YixingPACT Environmental Technology Company Ltd. ("PACT") has recently been awarded two contracts worth approximatelyUS$2.2 million in total. One project ...
2025-02-25 20:00
3331
Baidu Acquires JOYY's Live Streaming Business in China
BEIJING, Feb. 25, 2025 /PRNewswire/ -- Baidu, Inc. (NASDAQ: BIDU and HKEX: 9888 (HKD Counter) and 89888 (RMB Counter)) ("Baidu"), a leading AI company with strong Internet foundation, today announced that Baidu entered into agreements with JOYY Inc and acquired the video-based entertainment live ...
2025-02-25 19:00
2973
China Yuchai International Announces Unaudited 2024 Second Half-Year and Full Year Financial Results
SINGAPORE, Feb. 25, 2025 /PRNewswire/ -- China Yuchai International Limited (NYSE: CYD) ("China Yuchai" or the "Company"), one of the largest powertrain solution manufacturers through its main operating subsidiary inChina, Guangxi Yuchai Machinery Company Limited ("Yuchai"), wishes to announce to...
2025-02-25 19:00
4308
MicuRx Pharmaceutical: Contezolid Global Phase III Clinical Trial Safety and Efficacy Evaluation Endorsed by Data Monitoring Committee, Promising Prospects for Diabetic Foot Infection Treatment
* Data Monitoring Committee (DMC) has completed the first safety and efficacy assessment of the global Phase III clinical trial, recommending continued progression as planned * MRX-4 Injection followed by Contezolid Tablets demonstrated favorable safety and efficacy profiles in patients with...
2025-02-25 18:44
3179
WuXi XDC and LigaChem Biosciences Strengthen Partnership with Expanded MOU to Accelerate ADC Development
SHANGHAI, Feb. 25, 2025 /PRNewswire/ -- WuXi XDC Cayman Inc. ("WuXi XDC", or the "Company", stock code: 2268.HK), a leading global CRDMO (Contract Research, Development, and Manufacturing Organization) specializing in antibody-drug conjugates (ADCs) and other bioconjugates, today announced the si...
2025-02-25 18:34
2355
teamLab Phenomena Abu Dhabi Will Open on 18 April Within Saadiyat Cultural District Abu Dhabi
ABU DHABI, UAE, Feb. 25, 2025 /PRNewswire/ -- teamLab Phenomena Abu Dhabi will officially open its doors to the public in Saadiyat Cultural District Abu Dhabi on18 April 2025, announced by the Department of Culture and Tourism—Abu Dhabi (DCT Abu Dhabi), Miral, the leading creator of immersive des...
2025-02-25 18:33
2374
HUYA Inc. to Report Fourth Quarter and Fiscal Year 2024 Financial Results on Tuesday, March 18, 2025
-Earnings Webinar Scheduled for 6:00 a.m. ET on March 18, 2025- GUANGZHOU, China, Feb. 25, 2025 /PRNewswire/ -- HUYA Inc. ("Huya" or the "Company") (NYSE: HUYA), a leading game live streaming platform inChina, today announced that it will report its fourth quarter and fiscal year 2024 unaudited ...
2025-02-25 18:00
2337
Yatsen Announces Fourth Quarter and Full Year 2024 Financial Results
Conference Call to Be Held at 7:30 A.M. U.S. Eastern Time on February 25, 2025 GUANGZHOU, China, Feb. 25, 2025 /PRNewswire/ -- Yatsen Holding Limited ("Yatsen" or the "Company") (NYSE: YSG), a leadingChina-based beauty group, today announced its unaudited financial results for the fourth quarter ...
2025-02-25 18:00
3079
ZTO to Announce Fourth Quarter and Fiscal Year 2024 Financial Results on March 18, 2025 U.S. Eastern Time
SHANGHAI, Feb. 25, 2025 /PRNewswire/ -- ZTO Express (Cayman) Inc. (NYSE: ZTO and SEHK: 2057) ("ZTO" or the "Company"), a leading and fast-growing express delivery company in China, today announced that it will release its unaudited financial results for the fourth quarter endedDecember 31, 2024 a...
2025-02-25 17:00
2851
YolTech Therapeutics Announces Positive Clinical Data for YOLT-203, an In Vivo Gene Editing Therapy for Primary Hyperoxaluria Type 1 (PH1)
SHANGHAI, Feb. 25, 2025 /PRNewswire/ -- YolTech Therapeutics, a clinical-stage in vivo gene editing company committed to pioneering the next generation of precision genetic medicines, today reported positive results from the ongoing investigator-initiated trial (IIT) of YOLT-203 in patients with ...
2025-02-25 16:15
2323
CNPC's Well Shendi Take-1 reaches 10,910-meter milestone
BEIJING, Feb. 25, 2025 /PRNewswire/ -- A news report from chinadaily.com.cn: On February 20, China National Petroleum Corporation (CNPC) announced the successful completion of the Well Shendi Take-1, reaching an impressive depth of 10,910 meters. This groundbreaking achievement marks the well ...
2025-02-25 16:12
2325
ATRenew to Report Fourth Quarter and Full Year 2024 Financial Results on March 11, 2025
SHANGHAI, Feb. 25, 2025 /PRNewswire/ -- ATRenew Inc. ("ATRenew" or the "Company") (NYSE: RERE), a leading technology-driven pre-owned consumer electronics transactions and services platform in China, today announced that it plans to release its unaudited financial results for the fourth quarter a...
2025-02-25 16:00
2481
ChipMOS REPORTS FOURTH QUARTER AND FULL YEAR 2024 RESULTS
* 6.3% Increase in Full Year 2024 Revenue Compared to Prior Year * 13.0% Full Year 2024 Gross Margin Compared to 16.6% in 2023 * Full Year 2024 Net Earnings of NT$1.95 per Basic Common Share or US$1.19 per Basic ADS Compared to Net Earnings ofNT$2.60 per Basic Common Share or US$1.59 per Bas...
2025-02-25 16:00
2812
IIIF150 Unveils Latest Flagship Raptor 5G at MWC2025
BARCELONA, Spain, Feb. 25, 2025 /PRNewswire/ -- IIIF150, the imaginative ultra-thin rugged phone manufacture, announced their new flagship Raptor 5G which will be showcased inBarcelona, and different tests onsite to challenge the durability features. Being gratitude to Raptor users, IIIF150 confi...
2025-02-25 15:15
2936
BioCity Announces its selective Endothelin Type-A Receptor Antagonist, SC0062, Met the Primary Endpoint in Diabetic Kidney Disease (DKD) in a Phase 2 trial (2-SUCCEED)
SHANGHAI, Feb. 23, 2025 /PRNewswire/ -- BioCity Biopharma (BioCity) announced that its selective endothelin receptor type A (ETA) antagonist, SC0062, met the 12-week primary endpoint of a reduction in proteinuria in the diabetic kidney disease (DKD) cohort of its randomized, double-blind, placebo...
2025-02-25 14:48
11001
Week's Top Stories
Most Reposted
Visa and Lianlian Advance Trusted B2B Agentic Commerce Through LoopXPay's First Live B2B Agentic Transaction
[Picked up by 318 media titles]
2026-07-24 12:00
Ascentium Welcomes MGI Dobbyn Carafa, Strengthening Advisory Capability in Australia
[Picked up by 297 media titles]
2026-07-20 15:00
A New Chapter Begins: Peach Blossoms Returns to Level 5 with the Debut of its Black Pearl One Diamond Tasting Journey
[Picked up by 295 media titles]
2026-07-23 16:00
Phuket Marriott Resort & Spa, Merlin Beach Elevates Guest Experience with New Dining and Family Facilities
[Picked up by 293 media titles]
2026-07-24 18:32
Courtyard by Marriott Phuket, Patong Beach Wins TripAdvisor Best of the Best Award
[Picked up by 289 media titles]
2026-07-24 16:25
Most Read
Ascentium Welcomes MGI Dobbyn Carafa, Strengthening Advisory Capability in Australia
2026-07-20 15:00
16783
A New Chapter Begins: Peach Blossoms Returns to Level 5 with the Debut of its Black Pearl One Diamond Tasting Journey
2026-07-23 16:00
7839
Omni HR Launches Native MCP Integration, Connecting AI Assistants to Live HR Data
2026-07-20 11:00
7801
